Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07173543 · ClinicalTrials.gov registry record · NA

IH, Brain Health, and T2D

A NA study of Type 2 Diabetes and Aging, sponsored by Darren P Casey.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT07173543 is a NA study of Type 2 Diabetes and Aging that is actively recruiting participants, run by Darren P Casey. The registered enrollment target is 80 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07173543, a NA study of Type 2 Diabetes and Aging, is actively recruiting participants, sponsored by Darren P Casey.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).

Conditions Studied

Interventions

  • OTHER Intermittent Hypoxia 1 (IH1)
  • OTHER Intermittent Hypoxia 2 (IH2)
  • OTHER SHAM - normoxia

Study Locations (1)

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-09-22
Est. Completion 2028-06-30
Phase NA

Sponsor

Darren P Casey

3 total trials

What the Registry Record Tells You About NCT07173543

The ClinicalTrials.gov registry entry for NCT07173543 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (93% lower). The listed sponsor is Darren P Casey, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Intermittent Hypoxia 1 (IH1) is the first listed.

NCT07173543 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT07173543 about?

NCT07173543 is a clinical study titled "IH, Brain Health, and T2D". The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).

What is the current status of trial NCT07173543?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-09-22. Estimated completion is 2028-06-30.

What conditions does trial NCT07173543 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Aging.

What interventions are being tested in trial NCT07173543?

The interventions under investigation include: Intermittent Hypoxia 1 (IH1) (OTHER), Intermittent Hypoxia 2 (IH2) (OTHER), SHAM - normoxia (OTHER).

Who is sponsoring clinical trial NCT07173543?

This trial is sponsored by Darren P Casey, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07173543 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.